Transplanted hair is permanent but requires continued medical therapy to protect non-transplanted follicles
Summary
Hair loss affects a significant portion of both men and women, with androgenic alopecia (AGA) accounting for approximately 95% of male hair loss and at least half of female cases.1 While hair loss doesn't directly impact lifespan or traditional healthspan metrics, it can significantly affect emotional wellbeing and quality of life. Understanding the mechanisms, timing, and treatment options enables informed decision-making.
The key insight is that early intervention dramatically improves outcomes. Hair follicles don't completely die in androgenic alopecia—they miniaturize and produce progressively finer, shorter hairs due to DHT-mediated signaling through androgen receptors.2 However, once follicles reach a certain "breakpoint," they can no longer produce substantial hair. Starting treatment before this point, while follicles are still capable of producing normal hair, yields far better results than waiting until hair loss is visibly advanced.
This guide covers the science of hair loss, FDA-approved and off-label treatments, hair transplant procedures, and practical guidance on selecting specialists and treatment approaches for both men and women.
Prevalence of Androgenic Alopecia
Population
Prevalence
Timing
Men by age 50
30–50%1
Can begin in late teens/early 20s
Men by age 40
Virtually all cases manifest
Progressive over decades
Women across lifespan
20–50%1
Can begin as early as 40, sometimes not until 60
The Bottom Line
Hair loss is common, affecting up to 50% of men by age 50 and a similar proportion of women across their lifespan. The key to effective management is early intervention—starting treatment while follicles can still produce substantial hair yields dramatically better results than waiting until hair loss is visually obvious. Androgenic alopecia is driven by genetic sensitivity to DHT, not by DHT levels themselves, which is why lowering DHT remains an effective strategy even though high DHT isn't required for hair loss. For most people, starting with topical minoxidil and potentially adding a 5-alpha reductase inhibitor provides a foundation of treatment. More aggressive options—including oral medications, laser therapy, PRP, and ultimately hair transplantation—become appropriate as hair loss advances. Women should have other causes ruled out before assuming androgenic alopecia, and special considerations apply during pregnancy and perimenopause. Hair transplants are permanent when performed correctly, but require careful selection of surgeon and continued medical therapy to maintain non-transplanted hair. The most important message: if you're concerned about hair loss, starting treatment early—before significant loss is visible—provides the best opportunity for maintaining hair density long-term.
Continue Reading This Evidence-Based Guide
Free access to 235+ health education guides from Highland Longevity
No spam. Unsubscribe anytime.
Part 1: Understanding Hair Loss
Male vs. Female Hair Loss Patterns
Characteristic
Male Pattern
Female Pattern
Primary location
Temporal region and crown
Widening part, diffuse thinning
Progression
Predictable stages documented
More nuanced, less predictable
Visibility
Often progresses to significant balding
Less likely to experience significant balding
Other causes
AGA accounts for ~95%
Multiple other causes common
Other Causes of Hair Loss (Beyond AGA)
Cause
Notes
Iron deficiency
Common, easily tested
Thyroid dysfunction
Both hypo- and hyperthyroidism
Vitamin D deficiency
Often overlooked
B12 deficiency
Particularly in vegetarians/vegans
Autoimmune conditions
Alopecia areata, lupus
Psychological stress
Can trigger telogen effluvium
Hormonal changes
Pregnancy, menopause, PCOS
Medications
Rare: statins, antidepressants, antihypertensives
Part 2: The Science of Androgenic Alopecia
The Role of DHT
Concept
Explanation
DHT (Dihydrotestosterone)
More potent derivative of testosterone2
Conversion
Testosterone converted to DHT by 5-alpha reductase enzyme
Mechanism
DHT binds androgen receptors in dermal papilla cells2
Effect
Causes follicle miniaturization and shortened growth phase
Key insight
Sensitivity to DHT matters more than absolute DHT levels3
Why Sensitivity Matters More Than DHT Levels
Finding
Implication
No clear minimum DHT threshold for hair loss
Even low DHT can cause loss if follicles are sensitive
Genetically determined sensitivity
Family history is best predictor
DHT levels don't predict hair loss
Two men with identical DHT may have very different outcomes
Lowering DHT still helps
Reduces the signal reaching sensitive follicles
Genetic Factors
Relationship
Risk Increase
Father had hair loss (males)
~2x increased risk
Either parent had hair loss (females)
~85% increased risk
Nature of genetics
Polygenic (multiple genes involved)
Testing available
SNP screening through genetic services
Part 3: When to Start Treatment
The Critical Insight: Early Intervention
Concept
Detail
Hair density loss before visible
Can lose ~50% of hair density before it's noticeable
Normal density
80–100 follicular units per cm²
Each follicular unit
Contains 1–4 hair shafts
Visibly thin
Below ~50 follicular units per cm²
Visibly bald
Below ~10 follicular units per cm²
The Follicle "Breakpoint"
Stage
Characteristics
Early thinning
Follicles produce thinner, shorter hairs
Moderate progression
Hair shaft continues to miniaturize
Breakpoint reached
Follicles can only produce peach fuzz
Post-breakpoint
Treatment cannot restore substantial hair
Key point: Different areas of the scalp may be at different stages. Some regions may still be recoverable while others have passed the point of no return.
Diagnostic Tools
Tool
Purpose
Trichoscopy
Video scope examination of follicles, gold standard
Blood tests
Rule out iron deficiency, thyroid dysfunction, endocrine issues
Genetic testing
SNP screening for AGA-associated markers
Family history
Most practical initial assessment
Part 4: FDA-Approved Treatments
Overview of Treatment Options
Treatment
FDA Status
Mechanism
Topical minoxidil
FDA-approved
Vasodilator, anti-inflammatory
Oral finasteride
FDA-approved (men)
5-alpha reductase inhibitor
Low-level laser therapy
FDA-approved
ATP production, blood flow enhancement
Dutasteride
Off-label for hair loss
More potent 5-alpha reductase inhibitor
Spironolactone
Off-label
Androgen receptor inhibitor
Ketoconazole shampoo
Off-label
5-alpha reductase inhibitor, anti-inflammatory
PRP
Off-label
Platelet growth factors
Topical Minoxidil
Aspect
Detail
Available forms
2% solution, 5% solution, 5% foam
Application
1–2 times daily, massaged into scalp
Efficacy
~17 hairs/cm² increase (5% topical) vs placebo4
Advantages
Well-tolerated, inexpensive, first-line treatment
Limitations
Modest effect as monotherapy
Oral Minoxidil
Aspect
Detail
Status
Off-label for hair loss
Dosing
Women: 0.625–1 mg/day; Men: 1–5 mg/day5
Efficacy
~26–35 hairs/cm² increase at 24 weeks (5mg)5
Cautions
Interacts with blood pressure medications
Side effects
Hypertrichosis (17.5%), tachycardia (3.5%)5
Finasteride
Aspect
Detail
Mechanism
Blocks conversion of testosterone to DHT
Brand names
Propecia (1 mg), Proscar (5 mg)
Typical dose
1 mg daily
Efficacy
~12.4 hairs/cm² at 24 weeks, ~16.4 hairs/cm² at 48 weeks6
Side effects
Decreased libido, erectile dysfunction (uncommon)
Warning
Contraindicated in pregnancy; lowers PSA
Dutasteride
Aspect
Detail
Mechanism
More potent 5-alpha reductase inhibition
Typical dose
0.1–0.5 mg daily (some use 2–3x weekly)
Efficacy
~14 hairs/cm² at 0.5 mg/day
Considerations
Similar side effect profile to finasteride
Important
Both finasteride and dutasteride lower PSA levels, which can mask early prostate cancer. Men using these medications require careful PSA monitoring.
Clinical trials and meta-analyses comparing combination therapy to monotherapy:11
Outcome
Minoxidil Alone
Minoxidil + Finasteride
Hair density increase
~24 hairs/cm²
~29.68–34.5 hairs/cm²
Global improvement
Modest
OR 3.29 vs monotherapy
12-month response rate
—
92.4% stable or improved
Part 8: Sex-Specific Considerations
Considerations for Men
Factor
Guidance
Finasteride/dutasteride
First-line DHT reduction; monitor for sexual side effects
Spironolactone
Generally avoid due to anti-androgenic effects
PSA monitoring
Required if using 5-alpha reductase inhibitors
Post-finasteride syndrome
Rare but persistent sexual dysfunction after stopping
Considerations for Women
Factor
Guidance
Rule out other causes
Iron, thyroid, B12, hormonal changes
Pregnancy
Finasteride/dutasteride contraindicated
Perimenopause
Hormonal changes may contribute
Progesterone
Deficiency may contribute; supplementation sometimes helps
Spironolactone
Often effective option
5-alpha reductase inhibitors
Less effective in women than men
Part 9: Selecting a Specialist
Multidisciplinary Approach
Specialist
Role
Hair restoration physician
Primary coordinator, diagnostic evaluation
Dermatologist
Scalp conditions, medical treatments
Primary care
Blood work, overall health assessment
Endocrinologist
If hormonal causes suspected
Questions for Transplant Surgeons
Question
Why It Matters
Years of experience?
Skill develops over time
FUE vs FUT experience?
Different techniques require different expertise
Transection rate?
Should be 5–10% or less for FUE
Examples of scars from previous patients?
Shows quality of work
Why this approach for me?
Ensures personalized recommendation
Red Flags
Warning Sign
Indication
Unwilling to answer questions
Lack of transparency
One-size-fits-all approach
Not personalized
Pressure to decide quickly
Sales-focused rather than patient-focused
No discussion of alternatives
May not have patient's best interest
Part 10: Emerging Treatments
Note from Highland Longevity: The treatments listed below are discussed for educational purposes only. Highland Weight Loss & Wellness Clinic does not currently offer exosome therapy, stem cell therapy, or any other HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products). There are no FDA-approved exosome products, and the only FDA-approved stem cell products are blood-forming hematopoietic progenitor cells derived from umbilical cord blood, which we do not administer.
Treatments Under Investigation
Treatment
Status
Offered at Highland?
Exosome therapy
Not FDA-approved; limited data
No
Trans-epidermal growth factors
Experimental
No
Stem cell therapy
Early research phase; only umbilical cord blood-derived hematopoietic products are FDA-approved
No
Caution
Be skeptical of treatments lacking robust clinical evidence. The scalp is relatively easy to study, so effective treatments should have supporting data.
Part 11: Cost and Time Summary
Treatment
Approximate Cost
Time Commitment
Topical minoxidil
$20–50/month
1–2 applications daily
Oral finasteride
$20–50/month
Daily pill
Ketoconazole shampoo
$15–25/month
2–3x weekly
Spironolactone
$25/month
Daily
LLLT (at-home device)
$200–2,000 one-time
15–20 min, 3x weekly
PRP
$500–1,000/session
2–12 sessions/year
Hair transplant
$5,000–15,000/procedure
Surgery + recovery
Key Studies & Data
Finding
Result
Significance
AGA prevalence in men by age 50
30–50% affected
Most common form of hair loss
Finasteride 1mg efficacy
+12.4 hairs/cm² (24 wks), +16.4 (48 wks)
Sustained long-term benefit
Oral minoxidil 5mg efficacy
+26–35 hairs/cm² at 24 weeks
More effective than topical
Combination therapy (minoxidil + finasteride)
+29.68 hairs/cm²; OR 3.29 for marked improvement
Superior to monotherapy
LLLT efficacy
+19.8–25 hairs/cm² vs placebo
FDA-cleared devices effective
PRP meta-analysis
+25.09 hairs/cm² vs control
Activated PRP more effective
Spironolactone in women
85–100% prevent further thinning
Good option for FPHL
Additional Considerations
Study Limitations
Many hair loss studies have small sample sizes (100–300 participants)
Lack of standardized protocols for PRP preparation and delivery
Variable definitions of "improvement" across studies
Limited long-term data beyond 2 years for newer treatments
Most studies conducted in Caucasian populations with less data in other ethnic groups
Conflicting Evidence
Oral vs topical minoxidil efficacy shows comparable results in some studies, superior oral in others
PRP efficacy varies significantly based on preparation protocol and activation status
Ketoconazole benefits established but magnitude of effect uncertain
Dutasteride superior to finasteride in some studies but lacks FDA approval for hair loss
Individual Variation
Genetic sensitivity to DHT varies independently of hormone levels
Response to treatments highly variable; ~30% may be non-responders to any given therapy
AR gene variations account for ~40% of genetic risk for AGA
Women with underlying hormonal conditions (PCOS) may respond differently
Ethnic differences in prevalence and treatment response documented
Safety Notes
Finasteride/Dutasteride: Contraindicated in pregnancy; rare persistent sexual side effects reported; lowers PSA (may mask prostate cancer)
Oral Minoxidil: Cardiovascular effects require monitoring; contraindicated with certain blood pressure medications
Spironolactone: Hyperkalemia risk; menstrual irregularities common (37.5%)
5-alpha reductase inhibitors in men: Post-finasteride syndrome remains controversial but documented in case reports
Evidence Gaps
Limited head-to-head trials comparing all major treatments
Optimal dosing for oral minoxidil not established
Long-term safety data for combination therapies limited
Mechanisms of LLLT not fully understood
Stem cell and exosome therapies lack rigorous clinical data
Limited research on treatment discontinuation effects
Recent Developments
Topical finasteride showing promise with reduced systemic DHT suppression
Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014;176(3):687-695. doi:10.1016/j.ijcard.2014.07.079
Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. doi:10.1067/mjd.2002.124088
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. doi:10.1016/j.jaad.2021.02.054
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. doi:10.1016/s0190-9622(98)70007-6
Fabbrocini G, Cantelli M, Masarà A, et al. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Clin Cosmet Investig Dermatol. 2023;16:2487-2497. doi:10.2147/CCID.S428047
Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. doi:10.1159/000017954
Liu KH, Liu D, Chen YT, Chin SY. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2019;34(6):1063-1069. doi:10.1007/s10103-019-02723-6
Gentile P, Garcovich S. Systematic Review and Meta-Analysis of Platelet-Rich Plasma Use in Androgenetic Alopecia Compared to Minoxidil and Finasteride. Aesthet Surg J. 2023;43(9):NP656-NP668. doi:10.1093/asj/sjad087
Hu R, Xu F, Sheng Y, et al. The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis. JAAD Int. 2020;1(2):89-97. doi:10.1016/j.jdin.2020.06.001
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of January 2026 and may be updated as new evidence becomes available.
Have Questions About Men's Health?
A Highland provider can help you optimize testosterone, fertility, and overall health with evidence-based protocols.